Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers

被引:73
作者
Castera, L. [1 ,2 ]
Bernard, P. -H. [2 ]
Le Bail, B. [3 ]
Foucher, J. [1 ,2 ]
Trimoulet, P. [4 ]
Merrouche, W. [1 ]
Couzigou, P. [1 ]
de Ledinghen, V. [1 ]
机构
[1] CHU Bordeaux, Hop Haut Leveque, Serv Hepatogastroenterol, Pessac, France
[2] CHU Bordeaux, Hop St Andre, Serv Hepatogastroenterol, Bordeaux, France
[3] CHU Bordeaux, Hop Pellegrin, Serv Anatomopathol, Bordeaux, France
[4] CHU Bordeaux, Hop Pellegrin, Virol Lab, Bordeaux, France
关键词
NONINVASIVE ASSESSMENT; STIFFNESS MEASUREMENT; BIOCHEMICAL MARKERS; BIOPSY; DIAGNOSIS; FRANCE; ALGORITHMS; PREDICTION; INFECTION; FIBROTEST;
D O I
10.1111/j.1365-2036.2010.04547.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P>Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally in hepatitis B. Aim To evaluate longitudinally transient elastography (TE) and biomarkers for liver fibrosis assessment and follow-up of hepatitis B virus (HBV) inactive carriers. Methods Three hundred and twenty-nine consecutive HBeAg-negative HBV patients (201 inactive carriers) who underwent TE, Fibrotest and aspartate to platelet ratio index (APRI) the same day were studied. Results TE (median 4.8 vs. 6.8 kPa, P < 0.0001), Fibrotest (0.16 vs. 0.35, P < 0.0001) and APRI values (0.28 vs. 0.43, P < 0.0001) were significantly lower in inactive carriers than in the remaining patients whereas they did not differ among inactive carriers according to HBV DNA levels. In 82 inactive carriers with repeated examinations, although differences were observed among individual patients, TE values did not differ significantly over time (median intra-patient changes at end of follow-up relative to baseline: -0.2 kPa, P = 0.12). Conversely, significant fluctuations were observed for Fibrotest (+0.03, P = 0.012) and APRI (-0.01, P < 0.05). Eleven inactive carriers (5.5%) had initial elevated TE values (> 7.2 kPa) confirmed during follow-up in two with significant fibrosis (F2 and F3) on liver biopsy. Conclusion Non-invasive tools, particularly TE, could be useful, in addition to HBV DNA and transaminase levels, for follow-up of HBV inactive carriers as well as better selection of patients who require a liver biopsy.
引用
收藏
页码:455 / 465
页数:11
相关论文
共 52 条
[1]   Acute viral hepatitis increases liver stiffness values measured by transient elastography [J].
Arena, Umberto ;
Vizzutti, Francesco ;
Corti, Giampaolo ;
Ambu, Silvia ;
Stasi, Cristina ;
Bresci, Silvia ;
Moscarella, Stefania ;
Boddi, Vied ;
Petrarca, Antonio ;
Laffi, Giacomo ;
Marra, Fabio ;
Pinzani, Massimo .
HEPATOLOGY, 2008, 47 (02) :380-384
[2]  
Bedossa P, 2003, HEPATOLOGY, V38, p337A
[3]   An algorithm for the grading of activity in chronic hepatitis C [J].
Bedossa, P ;
Poynard, T .
HEPATOLOGY, 1996, 24 (02) :289-293
[4]  
BEDOSSA P, 1994, HEPATOLOGY, V20, P15
[5]   Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study [J].
Brunetto, MR ;
Oliveri, F ;
Coco, B ;
Leandro, G ;
Colombatto, P ;
Gorin, JM ;
Bonino, F .
JOURNAL OF HEPATOLOGY, 2002, 36 (02) :263-270
[6]   Practices of liver biopsy in France: Results of a prospective nationwide survey [J].
Cadranel, JF ;
Rufat, P ;
Degos, F .
HEPATOLOGY, 2000, 32 (03) :477-481
[7]   FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases [J].
Castera, L ;
Foucher, J ;
Bertet, J ;
Couzigou, P ;
De Ledinghen, V .
HEPATOLOGY, 2006, 43 (02) :373-374
[8]   Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C [J].
Castéra, L ;
Vergniol, J ;
Foucher, J ;
Le Bail, B ;
Chanteloup, E ;
Haaser, M ;
Darriet, M ;
Couzigou, P ;
De Lédinghen, V .
GASTROENTEROLOGY, 2005, 128 (02) :343-350
[9]  
Castéra L, 2001, AM J GASTROENTEROL, V96, P1553
[10]   Pain experienced during percutaneous liver biopsy [J].
Castéra, L ;
Nègre, I ;
Samii, K ;
Buffet, C .
HEPATOLOGY, 1999, 30 (06) :1529-1530